瘦型NAFLD:代谢适应差异塑造的独特疾病实体
该研究在活检证实的白人NAFLD患者(n=538)及瘦型健康对照(n=30)中,探讨胆汁酸、FGF19、基因变异和肠道菌群在瘦型NAFLD发病中的作用,并辅以小鼠模型。瘦型NAFLD患者代谢和组织学表现优于非瘦型,但胆汁酸和菌群谱存在差异,这些差异在早期纤维化阶段更明显。
要点
- 瘦型NAFLD患者代谢和组织学表现优于非瘦型患者(P < 0.05)。
- 瘦型NAFLD患者血清次级胆汁酸和FGF19升高、C4降低(P < 0.05)。
- 瘦型患者肠道菌群谱改变,小鼠模型重现相似表型。
核心结论
- 瘦型与非瘦型NAFLD患者间的代谢适应差异至少部分解释了其病理生理,并为治疗提供了选择。
研究设计与样本
- 在活检证实的白人NAFLD患者(n = 538)、瘦型健康对照(n = 30)及实验小鼠模型中,研究胆汁酸、FGF19、PNPLA3和TM6SF2变异及肠道菌群谱。
主要发现
- 瘦型NAFLD患者代谢和组织学表现优于非瘦型患者(P < 0.05 for all)。
- NAFLD晚期纤维化患者胆汁酸水平显著高于早期纤维化患者。
- 瘦型NAFLD患者血清次级胆汁酸和FGF19水平较高、C4水平较低(P < 0.05 for all),这些差异在早期纤维化阶段较晚期更明显(P < 0.05 for both)。
- 瘦型患者肠道菌群谱改变,瘦型和非瘦型小鼠模型重现相似发现。
- 给予小鼠顶端钠依赖性胆汁酸转运体抑制剂SC-435后,fgf15显著增加、胆汁酸和菌群谱改变,并改善瘦型模型中的脂肪性肝炎。
临床怎么用
- 瘦型与非瘦型NAFLD的代谢适应差异至少部分解释了病理生理,并为治疗提供了选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) affects a quarter of the adult population. A significant subset of patients are lean, but their underlying pathophysiology is not well understood. APPROACH AND RESULTS: We investigated the role of bile acids (BAs) and the gut microbiome in the pathogenesis of lean NAFLD. BA and fibroblast growth factor (FGF) 19 levels (a surrogate for intestinal farnesoid X receptor [FXR] activity), patatin-like phospholipase domain containing 3 (PNPLA3), and transmembrane 6 superfamily member 2 (TM6SF2) variants, and gut microbiota profiles in lean and nonlean NAFLD were investigated in a cohort of Caucasian patients with biopsy-proven NAFLD (n = 538), lean healthy controls (n = 30), and experimental murine models. Patients with lean NAFLD had a more favorable metabolic and histological profile compared with those with nonlean NAFLD (P < 0.05 for all). BA levels were significantly higher in NAFLD with advanced compared with earlier stages of liver fibrosis. Patients with lean NAFLD had higher serum secondary BA and FGF19 levels and reduced 7-alpha-hydroxy-4-cholesten-3-one (C4) levels (P < 0.05 for all). These differences were more profound in early compared with advanced stages of fibrosis (P < 0.05 for both). Lean patients demonstrated an altered gut microbiota profile. Similar findings were demonstrated in lean and nonlean murine models of NAFLD. Treating mice with an apical sodium-dependent BA transporter inhibitor (SC-435) resulted in marked increases in fgf15, a shift in the BA and microbiota profiles, and improved steatohepatitis in the lean model. CONCLUSIONS: Differences in metabolic adaptation between patients with lean and nonlean NAFLD, at least in part, explain the pathophysiology and provide options for therapy.
引用
- Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology. 2020. PMID: 31442319. doi:10.1002/hep.30908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。